Two clinical studies have shown that neoadjuvant anti-PD1 immunotherapy can improve survival and modify the tumor microenvironment in glioma patients indicating blocking of PD-1 could alter the tumor microenvironment and act in conjunction with CAR T treatment to lengthen the survival of glioma patients [132, 133]. The gene discussed is PDCD1; the disease is central nervous system cancer.